Subtype
AIDS-Related Malignant Neoplasm
CI-CAN-00000427Explore in graph →
12 active trials3 approved drugs
- NCIt
- C4046
Loading cancer entity…
Subtype
CI-CAN-00000427Explore in graph →
Clinical trials
66 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (11)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04929028 | Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer | active not recruiting | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jun 17, 2026 | clinicaltrials |
| NCT07539454 | Nirogacestat in Patients With Kaposi Sarcoma | not yet recruiting | Phase 2 | 28 | AIDS Malignancy ConsortiumNETWORK | 1 | May 28, 2026 | clinicaltrials |
| NCT06343311 |
| T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)(STARLIGHT-1) |
| recruiting |
| Phase 1 / Phase 2 |
| 21 |
| Estrella Biopharma, Inc.INDUSTRY |
| 1 |
| Aug 7, 2025 |
| clinicaltrials |
Data updated 22 days agoSource updated Jun 17, 2026source: clinicaltrials